Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DPH001
MIFTS: 59

Diphtheria

Categories: Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diphtheria

About this section

MalaCards integrated aliases for Diphtheria:

Name: Diphtheria 11 19 58 75 53 41 2 14 16 71 31 33
Corynebacterium Infections 43 71
Infection Due to Corynebacterium Diphtheriae 33
Corynebacterium Infection 11
Diphtherial Infection 33

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:11405
MeSH 43 D003354
SNOMED-CT 68 397434007
ICD10 31 A36 A36.9
MESH via Orphanet 44 D004165
ICD10 via Orphanet 32 A36.0 A36.1 A36.2 more
UMLS via Orphanet 72 C0012546
Orphanet 58 ORPHA1679
UMLS 71 C0010153 C0012546
Sources

Summaries for Diphtheria

About this section

MedlinePlus: 41 Diphtheria is a serious bacterial infection. You can catch it from a person who has the infection and coughs or sneezes. You can also get infected by coming in contact with an object, such as a toy, that has bacteria on it. Diphtheria usually affects the nose and throat. Symptoms include: Sore throat Swollen glands in the neck Fever Weakness Your doctor will diagnose it based on your signs and symptoms and a lab test. Getting treatment for diphtheria quickly is important. If your doctor suspects that you have it, you'll start treatment before the lab tests come back. Treatment is with antibiotics. The diphtheria, pertussis, and tetanus vaccine can prevent diphtheria, but its protection does not last forever. Children need another dose, or booster, at about age 12. Then, as adults, they should get a booster every 10 years. Diphtheria is very rare in the United States because of the vaccine. Centers for Disease Control and Prevention

MalaCards based summary: Diphtheria, also known as corynebacterium infections, is related to tetanus and allergic disease, and has symptoms including fever, pruritus and tinnitus. An important gene associated with Diphtheria is HBEGF (Heparin Binding EGF Like Growth Factor), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Aluminium phosphate and Edetate calcium disodium anhydrous have been mentioned in the context of this disorder. Affiliated tissues include heart, skin and kidney, and related phenotypes are Increased viability with SS1P at EC90 and growth/size/body region

GARD: 19 A rare bacterial infectious disease characterized by an affliction of the upper respiratory tract mediated by the toxin of Corynebacterium diphtheriae. Symptoms include formation of an inflammatory pseudomembrane, fever, sore throat, headaches, coughing, dysphagia, dyspnea, and prominently swollen cervical lymph nodes. The disease may lead to respiratory failure and severe toxin-mediated damage of internal organs, including the heart and kidneys. A cutaneous form of diphtheria is more common in tropical climates and usually follows an indolent course.

Orphanet: 58 A rare bacterial infectious disease characterized by an affliction of the upper respiratory tract mediated by the toxin of Corynebacterium diphtheriae. Symptoms include formation of an inflammatory pseudomembrane, fever, sore throat, headaches, coughing, dysphagia, dyspnea, and prominently swollen cervical lymph nodes. The disease may lead to respiratory failure and severe toxin-mediated damage of internal organs, including the heart and kidneys. A cutaneous form of diphtheria is more common in tropical climates and usually follows an indolent course.

Disease Ontology: 11 A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys.

CDC: 2 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. CDC recommends vaccines for infants, children, teens and adults to prevent diphtheria.

Wikipedia: 75 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Most infections are... more...
Sources

Related Diseases for Diphtheria

About this section

Diseases related to Diphtheria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 652)
# Related Disease Score Top Affiliating Genes
1 tetanus 32.0 IL2RA IL2 IL13
2 allergic disease 30.7 IL3 IL2 IL13 CSF2
3 primary cutaneous t-cell non-hodgkin lymphoma 30.5 IL2RB IL2RA IL2
4 respiratory failure 30.5 IL2 IL13 FURIN CSF2
5 leukemia, acute lymphoblastic 30.4 IL3RA IL3 IL2 CSF2 CD9
6 leukemia, acute myeloid 30.4 TFRC PARP1 IL3RA IL3 IL2 EGF
7 severe combined immunodeficiency 30.4 IL3 IL2RB IL2RA IL2 IL13 CSF2
8 viral infectious disease 30.4 IL2RA IL2 IL13 CD9
9 common cold 30.3 IL2 IL13 FURIN CSF2
10 acquired immunodeficiency syndrome 30.3 IL2RB IL2RA IL2 CSF2 CD9
11 juvenile rheumatoid arthritis 30.2 IL2RB IL2RA IL2
12 fungal infectious disease 30.2 IL2 IL13 CSF2
13 conjunctivitis 30.2 IL2RA IL2 IL13
14 cystitis 30.2 IL2 HBEGF EGF
15 hematologic cancer 30.1 IL3RA IL3 IL2RA IL2 CSF2
16 acute leukemia 30.0 IL3RA IL3 IL2 CSF2
17 immune deficiency disease 30.0 TFRC IL2RB IL2RA IL2 IL13 FURIN
18 sarcoidosis 1 30.0 IL2RB IL2RA IL2 IL13
19 skin disease 30.0 IL3 IL2 IL13 HBEGF EGF CSF2
20 tropical spastic paraparesis 30.0 IL2RB IL2RA IL2
21 t-cell acute lymphoblastic leukemia 29.9 TFRC IL3 IL2RB IL2RA IL2
22 meningitis 29.9 IL2 IL13 CSF2
23 severe covid-19 29.9 IL2 FURIN CSF2
24 contact dermatitis 29.9 IL2 IL13 CSF2
25 sezary's disease 29.9 IL2RB IL2RA IL2
26 human immunodeficiency virus infectious disease 29.9 IL2RA IL2 CSF2 CD9
27 bronchiolitis 29.8 IL2 IL13 CSF2
28 hypereosinophilic syndrome 29.8 IL3 IL2RA IL2 IL13 CSF2
29 leukemia, chronic lymphocytic 29.8 TFRC IL3RA IL2RA IL2 CSF2
30 behcet syndrome 29.7 IL2RA IL2 IL13 CSF2
31 pancytopenia 29.7 IL3RA IL3 IL2RA CSF2
32 rheumatoid arthritis 29.7 TFRC IL2RB IL2RA IL2 IL13 CSF2
33 malaria 29.6 TFRC IL3 IL2RB IL2RA IL2 IL13
34 neutropenia 29.6 TFRC PARP1 IL3 IL2 CSF2
35 arthritis 29.6 TFRC IL2RA IL2 IL13 CSF2
36 lymphoma, hodgkin, classic 29.6 IL3RA IL3 IL2RB IL2RA IL2 IL13
37 aplastic anemia 29.5 TFRC PARP1 IL3 CSF2
38 psoriasis 29.5 IL2RA IL2 IL13 HBEGF EGF
39 ovarian cancer 29.5 TFRC PARP1 IL3 IL2 HBEGF FURIN
40 dermatitis, atopic 29.4 IL3 IL2RB IL2RA IL2 IL13 CSF2
41 myelodysplastic syndrome 29.4 TFRC IL3RA IL3 EGF CSF2
42 myeloma, multiple 29.4 TFRC PARP1 IL3 IL2 HBEGF CSF2
43 combined immunodeficiency 29.3 TFRC IL3 IL2RB IL2RA IL2 IL13
44 diabetes mellitus 29.2 PARP1 IL2RA IL2 IL13 FURIN EGF
45 cutaneous diphtheria 11.7
46 pertussis 11.4
47 granulomatous lobular mastitis 11.1
48 poliomyelitis 10.9
49 haemophilus influenzae 10.9
50 measles 10.7

Comorbidity relations with Diphtheria via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Diphtheria:



Diseases related to Diphtheria
Sources

Symptoms & Phenotypes for Diphtheria

About this section

UMLS symptoms related to Diphtheria:


fever; pruritus; tinnitus; snoring; sore throat; coughing; vertigo/dizziness; equilibration disorder

GenomeRNAi Phenotypes related to Diphtheria according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with SS1P at EC90 GR00376-A-1 9.02 DNAJC24 DPH1 DPH2 DPH3 FURIN

MGI Mouse Phenotypes related to Diphtheria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 CD9 CSF2 DNAJC24 DPH1 DPH3 EEF2
2 nervous system MP:0003631 10.2 CD9 CSF2 DPH1 DPH3 FURIN HBEGF
3 immune system MP:0005387 10.18 CD9 CSF2 DPH2 EGF FURIN IL13
4 embryo MP:0005380 10.1 CSF2 DNAJC24 DPH1 DPH3 EEF2 FURIN
5 respiratory system MP:0005388 9.97 CD9 CSF2 DPH1 HBEGF IL13 IL2
6 hematopoietic system MP:0005397 9.97 CD9 CSF2 DPH1 DPH2 FURIN IL13
7 reproductive system MP:0005389 9.96 CD9 CSF2 EGF FURIN IL13 IL2
8 mortality/aging MP:0010768 9.89 CD9 CSF2 DNAJC24 DPH1 DPH2 DPH3
9 integument MP:0010771 9.28 CSF2 DPH1 EGF FURIN HBEGF IL13
Sources

Drugs & Therapeutics for Diphtheria

About this section

Drugs for Diphtheria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminium phosphate Approved, Investigational Phase 4 7784-30-7
2
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
3
Iron Approved Phase 4 7439-89-6 29936
4
Pentetic acid Approved Phase 4 67-43-6
5 Anti-Ulcer Agents Phase 4
6 Adjuvants, Immunologic Phase 4
7 Antacids Phase 4
8 Gastrointestinal Agents Phase 4
9 Antitoxins Phase 4
10 Fibrinolytic Agents Phase 4
11 Anticoagulants Phase 4
12 Iron Chelating Agents Phase 4
13 Antidotes Phase 4
14 Protective Agents Phase 4
15 Chelating Agents Phase 4
16 Calcium, Dietary Phase 4
17 Vaccines Phase 4
18 Immunologic Factors Phase 4
19 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
20 Immunoglobulins Phase 4
21 Antibodies Phase 4
22
Calcium Nutraceutical Phase 4 7440-70-2 271
23
Lactitol Approved, Investigational Phase 3 585-86-4 157355
24
Deferiprone Approved Phase 3 30652-11-0 2972
25 Pharmaceutical Solutions Phase 3
26 Cathartics Phase 3
27 Laxatives Phase 3
28 Somatomedin B Phase 3
29 Hemagglutinins Phase 3
30 Taxane Phase 3 108169
31 polysaccharide-K Phase 3
32 PENTA Phase 3
33
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
34
Sargramostim Approved, Investigational Phase 2 123774-72-1
35
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
36
Molgramostim Investigational Phase 2 99283-10-0
37 Antibodies, Monoclonal Phase 1
38 Immunoglobulins, Intravenous Phase 1
39
BCG vaccine Approved, Investigational
40
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical 63-91-2, 673-06-3 6140 71567
41 Anti-Bacterial Agents
42 Anti-Infective Agents
43
Serine Investigational, Nutraceutical 56-45-1 5951

Interventional clinical trials:

(show top 50) (show all 292)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Unknown status NCT04638985 Phase 4
2 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA) Unknown status NCT04636827 Phase 4
3 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
4 A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} Unknown status NCT04056728 Phase 4
5 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
6 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
7 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
8 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
9 Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age Completed NCT00601835 Phase 4
10 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
11 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
12 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
13 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexaâ„¢ or Infanrix-IPV/Hibâ„¢ Completed NCT01358825 Phase 4
14 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexaâ„¢ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
15 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
16 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
17 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
18 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
19 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
20 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
21 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
22 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
23 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
24 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
25 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACELâ„¢ and BOOSTRIX® Completed NCT00319553 Phase 4
26 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
27 Regulatory Post-Marketing Surveillance (PMS) Study for ADACELâ„¢ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
28 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
29 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIMâ„¢(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
30 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
31 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
32 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
33 Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development Completed NCT04543669 Phase 4
34 Prospective, Randomized, Controlled, Observer-Blind Trial to Measure the Efficacy, Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine and the Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Diphtheria Conjugate Vaccine in Pregnant Malian Women and Their Infants up to 6 Months of Age Completed NCT01430689 Phase 4
35 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
36 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
37 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
38 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
39 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
40 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
41 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
42 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
43 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
44 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIMâ„¢) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIMâ„¢ in the Study E2I34 Completed NCT01031303 Phase 4
45 Evaluation of GSK Biologicals' Boostrixâ„¢ in Healthy Adults, 10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
46 Assessment of the Immunogenicity and Safety of PENTAXIMâ„¢ in Philippines Completed NCT00254917 Phase 4
47 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactraâ„¢) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
48 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
49 Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrixâ„¢ (263855) in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
50 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4

Search NIH Clinical Center for Diphtheria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Diphtheria Antitoxin
Equine diphtheria antitoxin

Cochrane evidence based reviews: corynebacterium infections

Sources

Genetic Tests for Diphtheria

About this section
Sources

Anatomical Context for Diphtheria

About this section

Organs/tissues related to Diphtheria:

MalaCards : Heart, Skin, Kidney, Bone Marrow, T Cells, Bone, Myeloid
Sources

Publications for Diphtheria

About this section

Articles related to Diphtheria:

(show top 50) (show all 16204)
# Title Authors PMID Year
1
Ongoing toxin-positive diphtheria outbreaks in a federal asylum centre in Switzerland, analysis July to September 2022. 62 41
36330823 2022
2
Outbreak of imported diphtheria with Corynebacterium diphtheriae among migrants arriving in Germany, 2022. 62 41
36398576 2022
3
Role Of Methylprednisolone In Early Predicted Diphtheric Cardiomyopathy In Children: Is This A Solution? 62 41
36414582 2022
4
Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer. 53 62
19916021 2010
5
Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. 53 62
20138048 2010
6
Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. 53 62
19850947 2010
7
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. 53 62
19517064 2009
8
How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. 53 62
19818653 2009
9
Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. 53 62
19656414 2009
10
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. 53 62
19433964 2009
11
Urine podocyte mRNAs mark progression of renal disease. 53 62
19389856 2009
12
Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. 53 62
19221016 2009
13
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. 53 62
18992290 2009
14
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. 53 62
19689336 2009
15
Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. 53 62
19996587 2009
16
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. 53 62
19344187 2009
17
[Fluorescent derivatives of diphtheria toxin subunit B and their interaction with Vero cells]. 53 62
19877418 2009
18
A novel hairless mouse model on an atopic dermatitis-prone genetic background generated by receptor-mediated transgenesis. 53 62
18686008 2008
19
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. 53 62
18722270 2008
20
Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. 53 62
18599586 2008
21
Optimizing denileukin diftitox (Ontak) therapy. 53 62
18684057 2008
22
De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission. 53 62
18383317 2008
23
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. 53 62
18222985 2008
24
Dendritic cells are required for effective cross-presentation in the murine liver. 53 62
18213574 2008
25
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. 53 62
18297533 2008
26
Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. 53 62
18084721 2008
27
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I. 53 62
17915215 2008
28
Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. 53 62
17603081 2007
29
Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. 53 62
18089813 2007
30
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. 53 62
17975161 2007
31
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. 53 62
17544998 2007
32
Protective role of macrophages in noninflammatory lung injury caused by selective ablation of alveolar epithelial type II Cells. 53 62
17404282 2007
33
Inhibition of transferrin iron release increases in vitro drug carrier efficacy. 53 62
17239470 2007
34
Endogenous ADP-ribosylation of eukaryotic elongation factor 2 and its 32 kDa tryptic fragment. 53 62
17665640 2007
35
Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. 53 62
17187516 2007
36
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. 53 62
17200412 2007
37
A diphtheria toxin receptor deficient in epidermal growth factor-like biological activity. 53 62
17071947 2006
38
Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. 53 62
16882709 2006
39
Immunotoxins in the treatment of hematologic malignancies. 53 62
17073592 2006
40
Human alpha-defensins neutralize toxins of the mono-ADP-ribosyltransferase family. 53 62
16817779 2006
41
Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. 53 62
16892061 2006
42
Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. 53 62
16908626 2006
43
Immunotoxins for targeted cancer therapy. 53 62
17025272 2006
44
Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. 53 62
16645883 2006
45
Endogenous ADP-ribosylation for eukaryotic elongation factor 2: evidence of two different sites and reactions. 53 62
16142694 2006
46
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. 53 62
16595600 2006
47
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. 53 62
16586495 2006
48
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. 53 62
16314943 2006
49
Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. 53 62
16358262 2006
50
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. 53 62
16634908 2006
Sources

Variations for Diphtheria

About this section
Sources

Expression for Diphtheria

About this section
Search GEO for disease gene expression data for Diphtheria.
Sources

Pathways for Diphtheria

About this section


Pathways directly related to Diphtheria:

# Pathway Source
1 Uptake and function of diphtheria toxin Reactome 66

Pathways related to Diphtheria according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.75 CSF2 EGF HBEGF IL13 IL2 IL2RA
2
Signal Transduction 66
13.66 CSF2 EGF FURIN HBEGF IL2 IL2RA
3
Akt Signaling 64
Show member pathways
 13.33 IL3RA IL3 IL2RB IL2RA IL2 IL13
4
RAF/MAP kinase cascade 66
Show member pathways
 13.29 CSF2 EGF HBEGF IL2 IL2RA IL2RB
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.24 IL3RA IL3 IL2RB IL2RA IL2 IL13
6
p70S6K Signaling 64
Show member pathways
 12.96 IL3RA IL3 IL2RA IL2 HBEGF EGF
7
PAK Pathway 64
Show member pathways
 12.92 TXNRD1 IL3RA IL3 IL2RB IL2RA IL2
8
PI3K-Akt signaling pathway 74
Show member pathways
 12.88 IL3RA IL3 IL2RB IL2RA IL2 EGF
9
NF-kappaB Signaling 3
12.48 IL3 IL2RB IL2RA IL2
10
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.43 IL3RA IL3 IL2RB IL2RA IL2 IL13
11
Autophagy pathway 67
Show member pathways
 12.38 IL3RA IL2RB IL2RA FURIN
12
Interleukin-2 family signaling 66
Show member pathways
 12.14 IL3RA IL3 IL2RB IL2RA IL2 CSF2
13
Immune response Antigen presentation by MHC class II 22
Show member pathways
 12.08 IL2RB IL2RA IL2
14
MAPK Pathway 70
Show member pathways
 11.94 IL2RA IL2 IL13
15
IL2 signaling events mediated by STAT5 61
Show member pathways
 11.93 IL2RB IL2RA IL2
16
IL12-mediated signaling events 61
Show member pathways
 11.89 IL2RB IL2RA IL2
17
Immune response IL-2 activation and signaling pathway 22
Show member pathways
 11.81 IL2RA IL3 IL3RA
18
Allograft rejection 74
11.8 IL2RA IL2 IL13
19
Innate Lymphoid Cells Differentiation 65
11.73 IL2RB IL2RA IL2 IL13
20
Glucocorticoid receptor regulatory network 61
11.7 IL2 IL13 CSF2
21
Dendritic Cells Developmental Lineage Pathway 65
11.68 IL3RA IL2 CSF2
22
IL3-mediated signaling events 61
Show member pathways
 11.65 IL3RA IL3 CSF2
23
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.62 IL3 IL2RA IL2 CSF2
24
Lung fibrosis 74
11.59 IL13 EGF CSF2
25
Uptake and actions of bacterial toxins 66
Show member pathways
 11.55 CD9 EEF2 FURIN HBEGF TXNRD1
26
SHP2 signaling 61
11.51 IL2RB IL2RA IL2 EGF
27
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.5 IL3RA IL3 IL2RB IL2RA IL2 CSF2
28
Th2 Differentiation 65
11.42 IL2RB IL2RA IL2 IL13
29
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.29 CSF2 IL2 IL2RA IL2RB
30
Inflammatory response pathway 74
11.27 IL2RB IL2RA IL2
31
Gamma carboxylation, hypusine formation and arylsulfatase activation 66
Show member pathways
 11.2 FURIN EEF2 DPH7 DPH3 DPH2 DPH1
32
Immune infiltration in pancreatic cancer 74
11.17 IL2 IL13 CSF2
33
Cytokines and inflammatory response 74
11.17 IL3 IL2 IL13 CSF2
34
IL12 signaling mediated by STAT4 61
11.16 IL2RA IL2 IL13
35
Telomere Extension by Telomerase 64
Show member pathways
 11.15 IL2RB IL2RA IL2
36
G-protein signaling_Rap2B regulation pathway 22
10.96 CSF2 EGF IL13 IL2 IL3
37
Selective expression of chemokine receptors during T-cell polarization 74
10.84 IL2 CSF2
38
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) 66
10.65 IL2RA IL2
39
COVID-19 adverse outcome pathway 74
10.64 IL2RA IL2
Sources

GO Terms for Diphtheria

About this section

Cellular components related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.93 TFRC IL3RA IL2RB IL2RA IL13 CD9
2 interleukin-2 receptor complex GO:0005893 9.26 IL2RB IL2RA
3 clathrin-coated endocytic vesicle membrane GO:0030669 9.23 TFRC HBEGF EGF CD9

Biological processes related to Diphtheria according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of B cell proliferation GO:0030890 9.88 TFRC IL2 IL13
2 positive regulation of T cell proliferation GO:0042102 9.8 TFRC IL2RA IL2
3 activated T cell proliferation GO:0050798 9.78 IL2RA IL2
4 ERBB2-EGFR signaling pathway GO:0038134 9.73 HBEGF EGF
5 interleukin-2-mediated signaling pathway GO:0038110 9.62 IL2RA IL2RB
6 regulation of T cell homeostatic proliferation GO:0046013 9.56 IL2RA IL2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 IL3 IL2 IL13 CSF2
8 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2RA IL2
9 lymphocyte proliferation GO:0046651 9.46 IL2RA IL2
10 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.46 IL2RA IL2
11 peptidyl-diphthamide biosynthetic process from peptidyl-histidine GO:0017183 9.32 DPH7 DPH3 DPH2 DPH1 DNAJC24

Molecular functions related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-2 binding GO:0019976 9.56 IL2RB IL2RA
2 interleukin-2 receptor activity GO:0004911 9.46 IL2RB IL2RA
3 growth factor activity GO:0008083 9.32 IL3 IL2 HBEGF EGF CSF2
4 2-(3-amino-3-carboxypropyl)histidine synthase activity GO:0090560 9.26 DPH2 DPH1
Sources

Sources for Diphtheria

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....